

Melissa M Berrien-Elliott

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5898662/publications.pdf>

Version: 2024-02-01

48
papers

2,646
citations

257450

24
h-index

276875

41
g-index

50
all docs

50
docs citations

50
times ranked

4010
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. <i>Science Translational Medicine</i> , 2016, 8, 357ra123.	12.4	621
2	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. <i>Blood</i> , 2018, 131, 2515-2527.	1.4	307
3	CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. <i>Journal of Clinical Investigation</i> , 2017, 127, 4042-4058.	8.2	236
4	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. <i>Blood</i> , 2017, 129, 473-483.	1.4	147
5	CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. <i>Blood</i> , 2020, 136, 2308-2318.	1.4	133
6	Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. <i>Cancer Discovery</i> , 2020, 10, 1854-1871.	9.4	83
7	Human Cytokine-Induced Memory-Like Natural Killer Cells. <i>Journal of Innate Immunity</i> , 2015, 7, 563-571.	3.8	81
8	Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Acta Neuropathologica</i> , 2017, 133, 61-77.	7.7	72
9	Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 3744-3756.	7.0	69
10	Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development. <i>Developmental Cell</i> , 2020, 53, 229-239.e7.	7.0	63
11	Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	57
12	Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. <i>Blood</i> , 2022, 139, 1670-1683.	1.4	57
13	Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. <i>Science Translational Medicine</i> , 2022, 14, eabm1375.	12.4	49
14	Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and Fc γ RIIIa-Triggered Responses. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 398-404.	2.0	48
15	Memory-like natural killer cells for cancer immunotherapy. <i>Seminars in Hematology</i> , 2020, 57, 185-193.	3.4	48
16	Improving natural killer cell cancer immunotherapy. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 671-680.	1.6	44
17	MicroRNA-15/16 Antagonizes <i>Myb</i> To Control NK Cell Maturation. <i>Journal of Immunology</i> , 2015, 195, 2806-2817.	0.8	44
18	Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8+ T-Cell Tolerance. <i>Cancer Research</i> , 2013, 73, 605-616.	0.9	41

#	ARTICLE	IF	CITATIONS
19	Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. <i>Blood</i> , 2022, 139, 1177-1183.	1.4	41
20	Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity. <i>Cell Reports</i> , 2020, 31, 107720.	6.4	40
21	<i>MIR142</i> Loss-of-Function Mutations Derepress <i>ASH1L</i> to Increase <i>HOXA</i> Gene Expression and Promote Leukemogenesis. <i>Cancer Research</i> , 2018, 78, 3510-3521.	0.9	39
22	MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells. <i>Immunity</i> , 2019, 51, 479-490.e6.	14.3	39
23	A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 1071-1087.	3.4	36
24	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 4859-4869.	7.0	33
25	Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells. <i>Cancer Immunology Research</i> , 2015, 3, 116-124.	3.4	32
26	CD56 regulates human NK cell cytotoxicity through Pyk2. <i>ELife</i> , 2020, 9, .	6.0	30
27	Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 3339-3350.	7.0	26
28	Neuropilin-1 Expression Is Induced on Tolerant Self-Reactive CD8+ T Cells but Is Dispensable for the Tolerant Phenotype. <i>PLoS ONE</i> , 2014, 9, e110707.	2.5	21
29	Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2019, 134, 1954-1954.	1.4	19
30	Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 1999-2010.	1.4	17
31	Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes. <i>Cancer Immunology Research</i> , 2016, 4, 1016-1026.	3.4	15
32	CD8 ⁺ T Cell Exhaustion During Persistent Viral Infection is Regulated Independently of the Virus-Specific T Cell Receptor. <i>Immunological Investigations</i> , 2013, 42, 204-220.	2.0	10
33	Inflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional tolerance. <i>Journal of Leukocyte Biology</i> , 2014, 96, 397-410.	3.3	9
34	Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation. <i>Blood</i> , 2019, 134, 3307-3307.	1.4	9
35	Flow cytometry-based ex vivo murine NK cell cytotoxicity assay. <i>STAR Protocols</i> , 2021, 2, 100262.	1.2	8
36	Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses. <i>Blood</i> , 2019, 134, 3237-3237.	1.4	6

#	ARTICLE	IF	CITATIONS
37	A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 585-596.	4.4	5
38	Human Cytokine-Induced Memory-like NK Cells Exhibit in Vivo Anti-Leukemia Activity in Xenografted NSG Mice and in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 101-101.	1.4	4
39	Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing. <i>Blood</i> , 2015, 126, 574-574.	1.4	2
40	Abstract 1546: The CD30/CD16A bispecific innate immune cell engager AFM13 elicits heterogeneous single-cell NK cell responses and effectively triggers memory-like (ML) NK cells. , 2019, , .		2
41	Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors. <i>Blood</i> , 2019, 134, 869-869.	1.4	1
42	Cytokine-Induced Memory-like NK Cells Have a Distinct Single Cell Transcriptional Profile and Persist for Months in Adult and Pediatric Leukemia Patients after Adoptive Transfer. <i>Blood</i> , 2021, 138, 3825-3825.	1.4	1
43	Abstract LB-326: Identification of novel recurrent mutations in follicular lymphoma. , 2016, , .		0
44	Human CD56 ^{bright} NK Cells Acquire Potent Anti-Leukemia Functionality Following IL-15 Priming. <i>Blood</i> , 2016, 128, 550-550.	1.4	0
45	Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function. <i>Blood</i> , 2018, 132, 1271-1271.	1.4	0
46	Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development. <i>Blood</i> , 2019, 134, 2464-2464.	1.4	0
47	Eomes and T-Bet Expression Are Required By Mature Primary Human NK Cells for Anti-Leukemia Responses In Vivo. <i>Blood</i> , 2021, 138, 194-194.	1.4	0
48	531â€¦AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies. , 2020, , .		0